Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Prostatic Neoplasms 1Pleural Effusion, Malignant 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Melanoma 1Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 7Fluorouracil 5Cisplatin 5Leucovorin 3becatecarin 2Oxaliplatin 2Capecitabine 2trifluridine tipiracil drug combination 1trametinib 1titanium silicide 1spartalizumab 1seribantumab 1sargramostim 1pembrolizumab 1motexafin lutetium 1ixabepilone 1incomplete Freund's adjuvant 1durvalumab 1cediranib 1Trastuzumab 1Sutures 1Surgical Instruments 1Standard of Care 1S 1 (combination) 1Radiotherapy 1Radiosurgery 1Palonosetron 1Observation 1Liver Transplantation 1Ligation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Bile Duct Neoplasms × cediranib × Clear all
NCT01229111 2017-03-29

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

National Cancer Institute (NCI)

Phase 2 Terminated
14 enrolled 11 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡